支气管动脉化疗栓塞术在晚期非小细胞肺癌患者中的应用效果  

Application effect of bronchial arterial chemoembolization in patients with advanced non-small cell lung cancer

作　　者：刘愉 温娇 文丹 胡正清 胡文彬 LIU Yu;WEN Jiao;WEN Dan;HU Zhengqing;HU Wenbin(Department of Internal Medicine,Pingxiang Ganxi Cancer Hospital,Pingxiang 337000,Jiangxi,China)

机构地区：[1]萍乡赣西肿瘤医院内科,江西萍乡337000

出　　处：《癌症进展》2024年第16期1818-1821,共4页Oncology Progress

基　　金：江西省卫生健康委科技计划项目(202410774)。

摘　　要：目的探讨支气管动脉化疗栓塞术(BACE)+重组人血管内皮抑制素+程序性死亡受体1(PD-1)抑制剂在晚期非小细胞肺癌(NSCLC)患者中的应用效果。方法根据治疗方法的不同将60例晚期NSCLC患者分为A组(n=28)和B组(n=32),A组患者接受静脉化疗+重组人血管内皮抑制素+PD-1抑制剂治疗,B组患者接受BACE+重组人血管内皮抑制素+PD-1抑制剂治疗。比较两组患者的临床疗效、生活质量改善情况、T细胞亚群(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))水平及不良反应发生情况。结果B组患者治疗总有效率、生活质量改善率均高于A组,不良反应总发生率低于A组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)均高于本组治疗前,CD8^(+)水平均低于本组治疗前,B组患者CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)均高于A组,CD8^(+)水平低于A组,差异均有统计学意义(P﹤0.05)。结论BACE+重组人血管内皮抑制素+PD-1抑制剂治疗晚期NSCLC患者安全有效,能够改善患者的生活质量和T细胞亚群水平,降低不良反应发生率。Objective To investigate the application effect of bronchial arterial chemoembolization(BACE)+recombi-nant human endostatin+programmed cell death 1(PD-1)inhibitor in patients with advanced non-small cell lung cancer(NSCLC).Method A total of 60 patients with advanced NSCLC were divided into group A(n=28)and group B(n=32)according to different treatment methods.The group A received intravenous chemotherapy+recombinant human end-ostatin+PD-1 inhibitor treatment,and the group B received BACE+recombinant human endostatin+PD-1 inhibitor treat-ment.The clinical efficacy,improvement of quality of life,level of T cell subsets(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+))and in-cidence of adverse reactions were compared between the two groups.Result The total effective rate and improvement rate of quality of life in group B were higher than those in group A,the total incidence of adverse reactions was lower than that in group A,and the differences were statistically significant(P<0.05).After treatment,the CD3^(+),CD4^(+)levels and CD4^(+)/CD8^(+)in two groups were higher than those before treatment,the CD8^(+)levels were lower than those before treat-ment,the CD3^(+),CD4^(+)levels and CD4^(+)/CD8^(+)in group B were higher than those in group A,the CD8^(+)level was lower than that in group A,and the differences were statistically significant(P<0.05).Conclusion BACE+recombinant human endostatin+PD-1 inhibitor is safe and effective in the treatment of advanced NSCLC patients,which can improve the qual-ity of life of patients and the level of T cell subsets,reduce the incidence of adverse reactions.

关 键 词：支气管动脉化疗栓塞术 重组人血管内皮抑制素 程序性死亡受体1抑制剂 晚期非小细胞肺癌 应用效果 

分 类 号：R734.2[医药卫生—肿瘤]